Catalyst Pharmaceuticals (CPRX) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Business transformation and portfolio expansion

• Expanded from a single-product company to a diversified portfolio with three revenue streams, including Firdapse, Agamree, and Fycompa.

• Successfully launched Agamree while maintaining 15%-20% growth in Firdapse.

• Focused on buy-and-build strategy to attract new partnerships and acquisitions.

• Demonstrated ability to commercialize new acquisitions effectively.

• Entered the rare epilepsy space with Fycompa as a financial and strategic move.

Firdapse growth drivers and market strategy

• Maintains a robust patient pipeline by identifying misdiagnosed cases and engaging physicians.

• Recently approved to increase maximum daily dosage from 80mg to 100mg, expected to drive 5%-10% sales growth.

• Targets both non-tumor and tumor LEMS segments, with initiatives to improve diagnosis in oncology.

• Provides free diagnostic testing to oncologists to identify LEMS in small cell lung cancer patients.

• Confident in sustaining 15%-20% annual growth, with additional upside from oncology initiatives.

Intellectual property and competitive positioning

• Firdapse protected by six patents listed in the FDA Orange Book, expiring as late as February 2037.

• Recent legal settlements reinforce patent strength, with generic entry delayed to 2037.

• Dismissal of challenges by first generic filers signals strong IP position.

• Prior experience in IP management and pragmatic approach to litigation.

• Faced generic competition with Ruzurgi, but maintained market share due to superior patient support infrastructure.